Dylan Glubb PhD

Dylan Glubb After completing his BSc and MSc (Hons) at the University of Canterbury (NZ), Dylan worked for five years as a Research Scientist at Antisoma Research Limited (UK), developing antibody-enzyme fusion proteins for cancer therapy. He returned to New Zealand to carry out his PhD research into antidepressant pharmacogenomics at the University of Otago. Afterwards, he continued working at the University of Otago as a Research Fellow, studying the biological function of genes involved with inflammatory bowel disease. Dylan moved to the United States in 2009 to perform postdoctoral training, researching the functional genetics of the VEGF pathway and its relationship with cancer at the University of Chicago and, subsequently, the University of North Carolina, Chapel Hill. In 2013, Dylan began working at QIMR Berghofer and has undertaken the functional follow-up of large-scale genetic studies of breast, endometrial, and ovarian cancer to identify the likely causal variants and genes that mediate associations with cancer risk and survival.